MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Tandem Diabetes Care wins FDA clearance for insulin dosing via smartphone app

Tandem Diabetes Care wins FDA clearance for insulin dosing via smartphone app

By

Tandem mobile bolus
[Image from Tandem Diabetes Care]
Tandem Diabetes Care (NASDAQ:TNDM) today announced FDA clearance of bolus insulin dosing on the t:slim X2 insulin pump using the t:connect mobile app.

Company officials boasted that the t:connect mobile app is now the first smartphone app FDA-cleared for insulin delivery on both the iOS and Android operating systems.

Tandem Diabetes Care plans to roll out the mobile bolus feature update in the U.S. throughout the spring in a series of limited launch groups that it has already selected. The company plans an expanded launch later this summer.

Get the full story on our sister site Drug Delivery Business News. 

More recent news

About Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at [email protected].